XARELTO ® (rivaroxaban) Significantly Reduced Major Cardiovascular Events in Patients with Stable Coronary and Peripheral Artery Disease in Pivotal Phase 3 Study

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news